LALuybov V. Androsova

Luybov V. Androsova

*This is an algorithmically generated author record based on publicly available information.

Luybov V. Androsova has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Biological Significance of Neuroinflammation Indicators to Predict the Course of Amnestic Mild Cognitive Impairment

    by E. V. Ponomareva, S. I. Gavrilova, L. V. Androsova, S. A. Krinsky, О. В. Сенько, A. V. Kuznetsova, Yu. A. Сhaika, Ю. А. Чайка

    Background: neuroinfiammation which occurs as a long-term latent activation of systemic infiammation in the central nervous system is currently considered as one of the main pathogenetic mechanisms of the neurodegeneration progression in the brain of patients with Alzheimer’s disease. The aim of study is to research the prognostic significance of clinical and immunological parameters determined in the blood serum of patients with amnestic Mild Cognitive Impairment (aMCI) and to form an immunological profile that determines the further dynamics of the syndrome. Patients and Methods : 261 outpatient with aMCI were followed up at the FSBSI “Mental Health Research Centre” in the period from 2014 to 2023. The study participants underwent a general clinical examination and assessment of cognitive functions using a battery of psychometric tests and scales (MMSE, MoCA, CDT, tests of 10 words and 5 geometric shapes memorization, the Hachinski ischemic scale). In addition, patients underwent an initial level of cytokines study (TNFa, IL-1, IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10) in blood serum by enzyme immunoassay (ELISA); the levels of leukocyte elastase enzymatic activity (LE) and α1-proteinase inhibitor functional activity were determined in blood plazma by the spectrophotometric method. The protease inhibitory index was calculated. Conclusion: the cytokines set and immune response indicators have been identified. The distinguishing levels of TNFa, IL-6, IL-1b, LE predict various variants of three year course of aMCI including the conversion to dementia.


  • Open Access

    Comparative Characteristics of Inflammatory Markers in Alzheimer’s Disease in Males and Females

    by L. V. Androsova, N. M. Mikhaylova, S. A. Zozulya, A. G. Alekseeva, T. P. Klyushnik

    Background: the role of the sex factor in the differences between the manifestations of normality and pathology is not limited to the phenomenon of sexual dimorphism. It is known that the prevalence of certain diseases in males and females is different, in particular, there is a multiple increase in the incidence of dementia in females compared to males in Alzheimer’s disease (AD). Taking into account the role of neuroinflammation in the pathogenesis of neurodegenerative diseases, there is reason to assume gender differences in inflammation indicators at different stages of dementia in AD. The aim of the study was to conduct comparative analysis of indicators of the inflammatory system in the blood plasma of males and females at different stages of Alzheimer’s disease. Patients, control group and methods: a total of 210 patients with AD (101 males and 109 females) aged 49 to 94 years (average age 72.3 ± 8.2) with varying degrees of dementia severity, i.e. mild, moderate, severe, were examined. In peripheral blood plasma, the enzymatic activity of leukocyte elastase (LE) and the functional activity of α1-proteinase inhibitor (α1-PI) were determined by the spectrophotometric method, and the level of C-reactive protein (CRP) and IL-6 were determined by the enzyme-linked immunosorbent method (ELISA). The control group consisted of 52 healthy people, who did not differ from the patients in age and gender. Results and discussion: in the blood of patients with varying severity of dementia in AD, a statistically significant increase in α1-PI activity was observed compared to controls (p < 0.0001), regardless of gender. For all subgroups of patients with AD, the indicators of LE enzymatic activity were within the control range or beyond its lower limit. Low LE activity was observed in males compared to females both in the general group and in moderate dementia (p = 0.005105, p = 0.028672, respectively). In severe dementia, a significant decrease in LE activity compared to the controls did not depend on gender. Low LE activity in the blood of patients with AD, along with elevated levels of other inflammatory markers, may reflect a critical violation of the permeability of the blood-brain barrier and/or functional exhaustion of neutrophils due to a long-term inflammatory process. In males, compared with females, an increase in the level of the pro-inflammatory cytokine IL-6 was detected in the general group and in moderate dementia (p = 0.021238, p = 0.027894, respectively). A highly significant increase in CRP levels was only detected in males in subgroups with different severity of dementia. CRP levels in males were significantly higher than in females at the stage of moderate and severe dementia (p = 0.000906, p = 0.000049, respectively). Conclusion: distinctive features of inflammatory markers spectrum were identified, depending on gender and severity of dementia in AD. These results can be used to develop sex-specific preventive or therapeutic strategies for patients with mild cognitive impairment to determine risk and resistance to developing dementia.


  • Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study

    by E.V. Ponomareva, L.V. Androsova, S.A. Krynskiy, S.I. Gavrilova

    Objective. To study the efficacy and safety of long-term (3 years) course Cerebrolysin therapy in an open comparative study as a means potentially capable of slowing or preventing the transition of MCI into dementia, as well as to analyze the possibility of Cerebrolysin preventive effect predicting based on clinical and biological parameters. Material and methods. In total, 100 patients with aMCI were included in the study, randomly assigned to 2 groups: patients of group 1 (n=50) received annual course therapy with Cerebrolysin for 3 years (20 intravenous infusions of Cerebrolysin 20 ml in 100 ml of saline solution for 4 weeks). Group 2 patients underwent annual clinical examination, but did not receive therapy. All patients were monitored on an outpatient basis and were examined once a year. Clinical and psychopathological, psychometric, immunological, catamnestic, molecular genetic, and statistical methods were used. Results. A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy with Cerebrolysin and those who did not receive therapy showed a lower progression of cognitive deficits and a significantly lower conversion rate to dementia in patients who received annual courses for 3 years Cerebrolysin therapy compared with the comparison group. Conclusion. The data obtained indicate the presence of a disease-modifying effect in the annual course of Cerebrolysin and the possibility of using this drug in programs of dementia preventive therapy in people with a high risk of cognitive deficits progression and the dementia development in elderly patients with aMCI.

  • Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study

    by E.V. Ponomareva, L.V. Androsova, S.A. Krinsky, S.I. Gavrilova

    OBJECTIVE To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentially capable of slowing or preventing the transition of amnesic type mild cognitive impairment (aMCI) into clinically pronounced dementia in a three-year open comparative study, as well as to explore the possibility of predicting the preventive effect of such therapy based on a number of clinical and biological parameters. MATERIAL AND METHODS The study included 100 patients with aMCI, randomly divided into 2 groups: the therapeutic group consisted of 50 patients who received CA course therapy once a year for 3 years (20 intravenous infusions of 1000 mg (4 ml) in 100 ml of saline solution for 4 weeks) and a comparison group of 50 patients who underwent an annual examination at the center and did not receive therapy. Clinical and psychopathological, psychometric, immunological, follow-up, and statistical methods were used. RESULTS A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy of CA for 3 years and aMCI patients who did not receive therapy with similar initial demographic, diagnostic, psychometric and immunological characteristics showed a lower progression of cognitive deficits (12.2% and 39.1%, respectively) and a lower conversion rate (8.2% and 26.1%, respectively) to dementia in the therapeutic group compared with the comparison group. The differences between the initial and final (after 1, 2 and 3 years of follow-up) cognitive functioning indicators in the therapeutic group and the comparison group were significant (p<0.05) on all scales and tests in favor of the therapeutic group throughout the entire follow-up period. CONCLUSION The results allow us to consider CA as a possible model of preventive dementia therapy aimed at preventing the progression of cognitive deficits and the development of dementia in people at high risk of developing AD — patients with aMCI.


  • Clinical and psychopathological characteristics of patients with late-onset schizophrenia and schizophrenia-like psychoses in clusters identified by biological parameters

    by T.A. Prokhorova, L.V. Androsova, E.B. Tereshkina, I.S. Boksha, O.K. Savushkina, V.V. Pochueva, V.S. Sheshenin, G.SH. Burbaeva, T.P. Klyushnik

    OBJECTIVE To assess clinical and psychopathological characteristics of late-aged female patients with late-onset psychoses in clusters formed on the basis of biochemical and immunological blood parameters. MATERIAL AND METHODS We examined 59 women with schizophrenia and schizophrenia-like psychoses with onset after 40 years (ICD-10 F20, F22.8, F25, F23, F06.2), including 34 women with late-onset (40—60 years) and 25 with very late onset psychoses (after 60 years). At the time of hospitalization, a clinical/ psychopathological study was carried out using CGI-S, PANSS, CDSS, and HAMD-17, as well as the activities of glutathione reductase (GR) and glutathione-S-transferase (GT) have been determined in erythrocyte hemolysates, and the activities of leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) have been assessed in blood plasma. Biochemical and immunological parameters have been also determined in 34 age-matched mentally healthy women. RESULTS Clustering by signs such as GR, GT, LE and α1-PI has yielded two clusters of objects (patients) significantly different in GT (pppp=0.04) and higher total scores on PANSS subscales’ items. Cluster 1 includes 76% of patients with very late onset. Different correlations between clinical and biological signs are found in two clusters. CONCLUSION The identified clusters have different clinical and psychopathological characteristics. Dividing patients into subgroups according to biochemical and immunological parameters is promising for the search for differentiated therapeutic approaches.


  • Open Access

    Diagnostics and Assessment of the Severity of Alzheimer’s Disease: Machine Learning Algorithms Based on Markers of Inflammation

    by L. V. Androsova, A. N. Simonov, О. В. Сенько, N. M. Mikhaylova, A. V. Kuznetsova, T. P. Klyushnik

    Background: as the most common form of dementia, Alzheimer’s disease (AD) is characterized by cognitive deterioration and usually begins with loss of memory of recent events. It is important to search for biological, sensitive and affordable methods that could be used for early diagnostics of AD and determine the severity of the disease.Objective: to develop machine learning algorithms based on such inflammatory markers as the enzymatic activity of leukocyte elastase (LE) and the functional activity of the α1-proteinase inhibitor (α1-PI) for diagnosing and assessing the severity of AD.Patients and methods: the study included128 people aged 55 to 94 years (73.7 ± 7.9 years), of which 91 patients were diagnosed with Alzheimer’s disease and 37 apparently healthy people (control). The indicators of LE and α1-PI in blood plasma were used as classifying features for building models. The following algorithms were used to build a machine learning model: Optimal Valid Partition (OVP), logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosting (GB) and statistically weighted syndromes (WSWS). The predictive performance of the constructed classiers was evaluated by the overall accuracy (accuracy), sensitivity (sensitivity), specificity (specificity), F-measure and ROC-analysis.Results: the developed machine learning algorithms made it possible to reliably divide the general group of subjects (patients + conditionally healthy), as well as patients with different AD severity, into 4 quadrants of a two-dimensional diagram in the LE and α1-PI coordinates and showed close and fairly high predictive efficiency.Conclusion: the developed machine learning algorithms have proven close and sufficiently high prognostic efficacy for assessing the severity of AD based on inflammatory markers (enzymatic activity of LE and functional activity of α1-PI) and, probably, can be useful for early diagnostics of the disease and timely administration of therapy.


  • Open Access

    The Role of Inflammatory Markers for Diagnostics and Optimization of Therapy in Psychiatry

    by G. I. Kopeyko, T. P. Klyushnik, S. A. Zozulya, L. V. Androsova, O. A. Borisova

    Background: the results of studying the role of neuroinflammation in the pathogenesis of chronic mental disorders guide the scientific search for ways to apply conceptual notions to clinical practice. The aim: to present an overview of clinical and biological studies conducted jointly by clinicians and employees of the Laboratory of Neuroimmunology of the FSBSI “Mental Health Research Centre” and aimed at determination of the significance of immune biomarkers for the diagnosis, prognosis and treatment of various types of mental pathology. Method: the methodological equipment of this study is provided by the use of the original “Neuro-immuno-test” medical technology, developed at the FSBSI “Mental Health Researh Centre”, in comparison with the clinical data. Results and discussion: summarizing the results of many years of research showed that various inflammatory markers, determined in the blood of patients, can be used to assess the level of inflammation in the brain. Studies in various groups of patients showed that the level of these markers reflected the severity and acuteness of the pathological process in the brain and correlated with the characteristics of the clinical symptoms of patients. The most significant for an objective assessment of the clinical status of patients and the prognosis of the course of the disease are not individual inflammatory markers, but their combinations and ratios. It was found that the quantitative change in immunological parameters was ahead of the change in clinical indicators, confirming their prognostic significance. Elevated blood markers at the stages of the disease, preceding the development of pronounced clinical symptoms, can serve as an objective criterion for the presence of a current pathological process in the brain of patients with a high risk of manifestation of endogenous psychosis. The conducted immunological studies using the “Neuro-Immuno-Test” technology revealed different activation of the immune system in patients with cognitive impairment of varying severity, i.e. from mild cognitive impairment to dementia in Alzheimer's disease (AD). Conclusion: differences in immunophenotypes, which have certain quantitative and qualitative features of the spectrum of inflammatory and autoimmune markers, found using the “Neuro-Immuno-Test”, are extremely important both for diagnosis and prognosis, and for therapy optimization.

  • Open Access

    Predicting the Dynamics of Mild Cognitive Impairment According to Immunological Parameters

    by L. V. Androsova, Ye. V. Ponomaryova, A. N. Simonov, S. I. Gavrilova, T. P. Klyushnik, Е. В. Пономарёва

    Background: neuroin flammation is an important link in the pathogenesis of pre-dementia cognitive impairment and the development of dementia in Alzheimer’s disease.The aim of the study was to determine the prognostic value of inflaammatory markers (enzymatic activity of LE and its inhibitor alpha1-PI) at the stage of mild cognitive impairment for subsequent follow-up evaluation.Patients and methods: a total of 103 patients with an amnesic type of mild cognitive impairment (aMCI) aged 50 to 89 years (mean age 68.1 ± 9.4 years) were examined. Mental status of the patients was assessed clinically and by psychometric scales and tests. After 3 years of observation, the patients were divided into two groups depending on the dynamics of cognitive status: the 1st group consisted of 49 patients with progression of cognitive decline to the degree of dementia; the 2nd group included 54 patients with a stable state of cognitive functions. The control group included 61 subjects of the same age and gender. The enzymatic activity of leukocyte elastase (LE) and the functional activity of the α1-proteinase inhibitor (α1-PI) were determined in blood plasma. Cluster analysis was used to isolate immunotypes.Results: the functional activity of α1-PI at the starting point of the study in patients of both follow-up groups exceeded the control values (p = 0.000001, p = 0.000006, respectively). Follow-up groups differed in LE activity at the initial stage. In patients of the 1st group (with an increase in cognitive impairment) LE activity did not differ from the control values (p = 0.144651). Group 2 (with stable cognitive functions) was characterized by a significantly higher LE activity compared to the controls (p = 0.000000). Cluster analysis made it possible to identify two immunotypes that differed in LE activity. In the 1st cluster, LE activity was within the control range and below, it mainly included patients of the 1st follow-up group (68.3%). In the 2nd cluster LE activity exceeded the control values, this cluster mainly consisted of patients of the 2nd follow-up group (85.0%) (χ2 = 27.82, p = 0.0000).Conclusion: the revealed reliable differences in the distribution of follow-up groups for immunological clusters indicate the possibility of using indicators of LE and α1-PI activity for diagnosing and predicting the dynamics of mild cognitive decline.


  • Inflammatory markers in organic nonpsychotic disorders

    by L.V. Androsova, T.P. Vetlugina, V.B. Nikitina, S.A. Zozulya, I.N. Otman, M.F. Belokrylova, T.P. Klyushnik

    ЦЕЛЬ ИССЛЕДОВАНИЯ Определение показателей системного воспаления в образцах периферической крови больных с органическими непсихотическими расстройствами. МАТЕРИАЛ И МЕТОДЫ В обследование были включены 60 пациентов в возрасте 56,9±7,7 года, с длительностью заболевания 7,3±5,55 года, с верифицированным диагнозом по МКБ-10 «Органическое эмоционально лабильное (астеническое) расстройство» (F06.6) и «Органическое тревожное расстройство» (F06.4). Пациенты с органическим астеническим расстройством по преобладающим в клинической картине симптомам были разделены на две группы: 36 пациентов с астено-цефалгическим синдромом (АЦ); 10 пациентов с астенодистимическим синдромом (АД); в третью группу (14 человек) включены пациенты с органическим тревожным расстройством (ТР). Контрольную группу составили 65 человек, сопоставимых по возрасту и полу с пациентами. Активность лейкоцитарной эластазы (ЛЭ) и α1-протеиназного ингибитора (α1-ПИ) определяли спектрофотометрическим методом, уровни аАТ к S100b и ОБМ — иммуноферментным. Вычислялся протеазно-ингибиторный индекс (ПИИ) — соотношение активности ЛЭ к α1-ПИ. РЕЗУЛЬТАТЫ Показано статистически значимое повышение энзиматической активности ЛЭ (235,4 [216,4; 258,1] нмоль/мин*мл, p<0,001), функциональной активности α1-ПИ (43,1 [38,7; 47,6] ИЕ/мл, p<0,001), уровня аАТ к S100b (0,78 [0,70; 0,89] ед.опт., p<0,05) и снижение ПИИ (6,19 [5,32; 6,9], p<0,05) по отношению к контролю в общей группе пациентов с органическими непсихическими расстройствами. Отклонения от нормальных показателей иммунных маркеров воспаления в образцах крови выявлено и при разных синдромах. Кластеризация общей группы пациентов по активности ЛЭ позволила выделить 2 иммунотипа со сбалансированным и несбалансированным воспалительным процессом, подтверждающие клиническое разнообразие заболевания: 60% пациентов с АЦ относятся к 1-му кластеру, при котором соотношение иммунных маркеров характеризует сбалансированный воспалительный процесс, нацеленный на восстановление гомеостаза; 80% пациентов с ТР относятся ко 2-му кластеру, который характеризует низкую протеолитическую активность и дисбаланс воспаления, что является неблагоприятным прогностическим фактором в плане дальнейшего течения заболевания и терапии. ЗАКЛЮЧЕНИЕ Полученные результаты подтверждают значимость воспалительного звена в нейропрогрессировании органических непсихотических расстройств. Выявленные особенности иммунного ответа могут служить дополнительным параклиническим критерием для дифференциальной диагностики и оценки прогноза дальнейшего развития заболевания.


  • Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment

    by I.V. Kolykhalov, L.V. Androsova, S.I. Gavrilova

    ЦЕЛЬ ИССЛЕДОВАНИЯ Определить динамику параметров клинико-иммунологической оценки состояния больных с синдромом мягкого когнитивного снижения амнестического типа (aMCI) в процессе проведения курсовой терапии холином альфосцератом (α-ГФХ) для разработки системы мониторинга и прогнозирования ее эффективности у лиц из группы риска развития болезни Альцгеймера (БА). МАТЕРИАЛ И МЕТОДЫ Тридцать пациентов в возрасте от 56 до 82 лет (средний возраст 68,8±9,4 года) с aMCI получали в течение 3 мес курсовую терапию α-ГФХ в капсулах по 400 мг 3 раза в день (1200 мг/сут). Оценка эффективности терапии по психометрическим тестам и шкалам проводилась трижды (0, 45 и 90-й дни терапии), дважды (0 и 90-й дни): оценивались иммунологические показатели — лейкоцитарная эластаза (ЛЭ) и α1-протеазный ингибитор (α1-ПИ). РЕЗУЛЬТАТЫ Было показано, что курсовое лечение α-ГФХ позволяет получить хороший терапевтический эффект в отношении как когнитивных функций, так и ряда иммунологических показателей у пациентов с aMCI. Выявленные значимые клинико-иммунологические корреляции между выраженностью улучшения когнитивных функций (по шкале MMSE и Бостонскому тесту называния 29 [28; 29] и 30 [29; 30] (p<0,05); 52 [51; 53] и 54 [52; 55] (p<0,05) на 45-й и 90-й дни терапии соответственно) и повышением уровня ЛЭ (229,0 [207,0; 246,2] нмоль/мин·мл, (p<0,05)) после завершения курсовой терапии α-ГФХ позволяют предположить, что связь между повышением активности ЛЭ может рассматриваться в качестве потенциального маркера позитивного терапевтического ответа на лечение α-ГФХ у пациентов с aMCI. ЗАКЛЮЧЕНИЕ Проведенное исследование показало возможность использования иммунологических показателей в качестве прогностических маркеров терапии и необходимость дальнейших исследований роли иммунных механизмов в терапевтическом эффекте α-ГФХ при aMCI.